The Questionable Diverse Effect of Agomelatine On Cisplatin Keratotoxicity

Karaca U.

6 th International Medicine and Health Sciences Researches Congress, Ankara, Türkiye, 10 - 11 Nisan 2021, cilt.1, ss.651-657

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Cilt numarası: 1
  • Basıldığı Şehir: Ankara
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.651-657


Objectives: The high blood flow and rapid metabolic activity of the retina and choroid are the main reasons why the eye is susceptible to toxic effects under cisplatin therapy. Therefore, it is necessary to investigate and uncover possible mechanisms to find ways to prevent the toxic effect. The present study aimed to investigate the effects of agomelatine on cisplatin-induced keratotoxicity by histopathological analyzes. Methods: Animals were administered with cisplatin (7 mg/kg, i.p.) and treated with agomelatine (20 and 40 mg/kg, p.o) for seven days. Histopathological analysis was performed to determined structural changes in corneal tissue. In histopathological examination performed with 40x objective; corneal epithelial irregularity and hyperplasia were evaluated under the headings of corneal, stromal inflammatory infiltration, and stromal edema, and histopathological scoring were performed. Key findings: Histopathological analysis was performed to observe and evaluate the effects of agomelatine on the cornea. Corneal epithelial thickness was naturally observed in the sections belonging to the control group. Corneal stroma was also observed in natural appearance; there were no signs of stromal inflammatory infiltration or edema. Signs of irregularity and hyperplasia in the corneal epithelium were observed in sections belonging to the cisplatin group. Inflammatory cell infiltration and edema in some areas were observed in the corneal stroma. A decrease in histopathological findings was observed in the cisplatin + agomelatine 20 mg/kg group compared to the cisplatin group. In the cisplatin + agomelatine 40 mg/kg group, there was a decrease in stromal edema compared to the cisplatin group, but no significant reduction in other histopathological findings. Conclusions: Our results provide evidence for the possible protective action of agomelatine in cisplatin treatment. Hence, it is clear that our results need to be investigated in more detail for the responsible mechanism underlying this discrepancy.